Denver, CONCT06521502Now EnrollingIRB Ready

ARDS Clinical Trial in Denver, CO

Access cutting-edge ards treatment through this clinical trial at a research site in Denver. Study-provided care at no cost to qualified participants.

Sponsored by Vanderbilt University Medical Center

Quick Self-Assessment

See if you qualify for this Denver location

Preparing your pre-screening questions…

Expert Care in Denver

Access ards specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ards treatment provided free

Apply for This Denver Location

Check if you qualify for this ards clinical trial in Denver, CO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Denver

    Convenient for CO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Denver site if eligible
  4. 4Begin participation

About This ARDS Study in Denver

The goal of the observational APS phenotyping study is to better understand risk factors, potential biomarkers, length and severity of illness, and recovery for adults with ARDS, pneumonia, and/ or sepsis. This study will also generate a biobank of specimens collected from these patients that will be available to investigators for future studies of ARDS, sepsis, and/or pneumonia.

Sponsor: Vanderbilt University Medical Center

Who Can Participate

Inclusion Criteria

To be eligible for enrollment, a patient must meet all the following inclusion criteria at the time of the first study-specified biospecimen collection (Time 0):
Age ≥ 18 years old
Admitted (or planned to be admitted) to an intensive care unit (ICU) or other in-patient hospital location where IV vasopressors or advanced respiratory support (invasive mechanical ventilation, non-invasive ventilation, or high flow nasal cannula) are routinely provided (referred to as an "eligible unit.")
Acute cardiovascular or pulmonary organ dysfunction defined by meeting at least one of the two criteria below:
New receipt of invasive mechanical ventilation, non-invasive ventilation, high flow nasal cannula, or supplemental oxygen at a flow rate of ≥ 6 lpm for acute hypoxemia. a. Patients who use chronic oxygen therapy are eligible to participate if they are receiving at least 6 lpm higher than their baseline oxygen requirement (e.g., a patient on 3 lpm O2 at baseline is eligible if they require ≥9 lpm for hypoxemia) or are started on advanced respiratory support (invasive mechanical ventilation, non- invasive ventilation, or high flow nasal cannula).
Receipt of intravenous infusion of a vasopressor medication for at least one hour.
Acute cardiovascular or pulmonary organ dysfunction (inclusion criterion #3) is attributed to an acute inflammatory condition, including but not limited to any of the following:
Any infection including pneumonia.
Aspiration pneumonitis.
Pancreatitis.
Auto-inflammatory condition such as:
Hemophagocytic lymphohistiocytosis.
Suspected acute rheumatologic or auto-immune disease with pulmonary or cardiovascular manifestations.
Suspected cryptogenic organizing pneumonia presenting acutely.
Suspected diffuse alveolar hemorrhage.
Suspected acute anaphylaxis.
Suspected acute pulmonary drug toxicity.

Exclusion Criteria

To be eligible for enrollment, a patient must not meet any of the following exclusion criteria at the time of the first study-specified biospecimen collection (Time 0):
Patient/legally authorized representative (LAR) declines participation.
Acute cardiovascular or pulmonary organ dysfunction (inclusion criterion #3) has been present for \> 48 hours.
Patient has been in an eligible unit (inclusion criterion #2) for more than 120 hours (five days).
Patient is no longer expected to meet the acute cardiovascular or pulmonary organ dysfunction inclusion criterion (inclusion criterion #3) 24 hours after enrollment.
Patient desires comfort measures only.
Patient is a prisoner.
Patient had out-of-hospital cardiac arrest leading to this hospitalization.
Residence immediately before this hospitalization in a long-term acute care facility.
Presence of tracheostomy for respiratory failure.
Home invasive mechanical ventilation or non-invasive ventilation (except patients with non-invasive ventilation prescribed as a treatment for a sleep disorder may participate).
Suspected cause of the patient's acute cardiovascular and/or pulmonary dysfunction (inclusion criterion #3) is an alternative condition (not ARDS, pneumonia, or sepsis), including but not limited to the list below:
Drug overdose (without aspiration, lung injury, pneumonia, or infection).
Trauma (without aspiration, pneumonia, or infection).
Chronic lung disease without suspected infection, aspiration, or inflammation.
Asthma, chronic obstructive pulmonary disease (COPD), sarcoidosis, interstitial lung disease, neuromuscular respiratory failure.
Status epilepticus.
Acute pulmonary embolism.
Acute decompensated heart failure.
Diabetic ketoacidosis.
Acute stroke or intracranial hemorrhage.
Acute bleeding (GI bleeding, post-procedural bleeding, hemolysis).
Cytokine release syndrome due to chemotherapy.
Inability or unwillingness to complete study-specified blood draws, for example, due to local policies about hemoglobin thresholds for research blood draws.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Denver?

Yes, this clinical trial (NCT06521502) has an active research site in Denver, CO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

ARDS Treatment Options in Denver, CO

If you're searching for ards treatment options in Denver, CO, this clinical trial (NCT06521502) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Denver research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ards specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Ready to Join in Denver?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Denver, CO